Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Preparing word cloud

×

Search

Type in a keyword to search

Filter by last modified time
See new records

Current Facets and Filters

  • Keywords:clinical (facet)
  • Website Status : Ascending

Facets

Sort alphabetically | Sort by count

Recent searches

SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.

(last updated: Sep 14, 2019)

Physical Resource or Software Tool Software

514 Results - per page

Resource NameResource TypeDescriptionKeywordsResource IDProper CitationParent OrganizationRelated ConditionFunding AgencyRelationReferenceWebsite StatusAlternate IDsAlternate URLsOld URLs
PatientCrossroadsResource, patient registry, topical portal, portal, people resource, data or information resourceA trusted third-party gatekeeper of patient data from participants in a rare disease ecosystem, collecting and managing the information in a scalable, cost-effective manner. Each patient registry provides critical disease knowledge which makes that disease easier to study, increasing the probability a treatment can be developed. PatientCrossroads takes a network approach to patient registry programs. Unlike companies that merely sell registry software, we offer a full range of administration, management, and genetic curation services. What does this consolidated, patient-centric approach to patient registries mean? * Patients can more easily find registries and provide their valuable data (including locations of blood and tissue samples as well as reports of diagnoses, disease symptoms, treatment usage, and lifestyle activities) * Patients can be confident in the privacy of their de-identified data and the knowledge that PatientCrossroads does not sell patient data * Researchers and pharmaceutical companies have a larger, more easily accessible pool of potential patients for research studies and clinical trials targeting specific rare diseases * Pharmaceutical companies can collect post-market surveillance data in a more scalable and cost-effective manner * Rare disease advocacy and research foundations can more easily organize their global patient populations for inclusion in trials and studiesdisease, treatment, clinical, patient, registry, drug discovery, clinical trial, research study, genetics, biorepositorySCR_006279(PatientCrossroads, RRID:SCR_006279)Rare diseaseLast checked downnlx_151889
CardioGenomicsResource, topical portal, portal, data or information resourceThe primary goal of the CardioGenomics PGA is to begin to link genes to structure, function, dysfunction and structural abnormalities of the cardiovascular system caused by clinically relevant genetic and environmental stimuli. The principal biological theme to be pursued is how the transcriptional network of the cardiovascular system responds to genetic and environmental stresses to maintain normal function and structure, and how this network is altered in disease. This PGA will generate a high quality, comprehensive data set for the functional genomics of structural and functional adaptation of the cardiovascular system by integrating expression data from animal models and human tissue samples, mutation screening of candidate genes in patients, and DNA polymorphisms in a well characterized general population. Such a data set will serve as a benchmark for future basic, clinical, and pharmacogenomic studies. Training and education are also a key focus of the CardioGenomics PGA. In addition to ongoing journal clubs and seminars, the PGA will be sponsoring symposia at major conferences, and developing workshops related to the areas of focus of this PGA. Information regarding upcoming events can be found in the Events section of this site, and information about training and education opportunities sponsored by CardioGenomics can be found on the Teaching and Education page. The CardioGenomics project came to a close in 2005. This server, cardiogenomics.med.harvard.edu, remains online in order to continue to distribute data that was generated by investigators under the auspices of the CardioGenomics Program for Genomic Applications (PGA). :Sponsors: This resource is supported by The National Heart, Lung and Blood Institute (NHLBI) of the NIH.genomics, clinical, genetic, environmental, stimulus, cardiovascular, disease, data, expression, gene, dna, polymorphism, population, pharmacogenomic, training, educationSCR_007248(CardioGenomics, RRID:SCR_007248)Harvard University; Cambridge; United States Last checked downnif-0000-30296http://www.cardiogenomics.org
International Database of Tetrahydrobiopterin DeficienciesResource, data or information resource, databaseTHIS RESOURCE IS NO LONGER IN SERVICE, documented on August 26, 2016. The BIODEF database have tabulated the most common clinical and laboratory data related to hyperphenylalaninaemia and tetrahydrobiopterin deficiencies. Additionally, there are data regarding treatment, outcome, and DNA analysis. Approximately 2% of newborns with hyperphenylalaninaemia are deficient in tetrahydrobiopterin. Selective screening must be performed in all instances where hyperphenylalaninaemia is detected by neonatal screening. In the last 20 years, 308 patients with tetrahydrobiopterin deficiencies have been recognized as a result of screening carried out, worldwide, in Departments of Paediatrics. Of these 308 patients, 181 suffered from 6-pyruvoyltetrahydropterin synthase deficiency, 92 from dihydropteridine reductase deficiency, 13 from pterin-4a-carbinolamine dehydratase deficiency, 12 from GTP cyclohydrolase I deficiency, and 10 are still unclassified. The BIODEF database have tabulated the most common clinical and laboratory data related to hyperphenylalaninaemia and tetrahydrobiopterin deficiencies. Additionally, there are data regarding treatment, outcome, and DNA analysis. Preliminary evaluation reveals that the degree of hyperphenylalaninaemia can vary from normal to 2500 mumol/L. Analyses of pterins in urine and measurement of dihydropteridine reductase activity from Guthrie cards are absolutely essential tests for accurate diagnosis. There is a regional (demographic) variation in the frequency of tetrahydrobiopterin deficiencies indicating the highest incidence in Saudi Arabia, probably a consequence of the high consanguinity rate.ethnic, frequency, 6-pyruvoyltetrahydropterin synthase deficiency, analysis, bh4, clinical, deficiency, demographic, diagnosis, dihydropteridine reductase deficiency, dna, gtp cyclohydrolase i deficiency, hyperphenylalaninaemia, measurement, neonatal, origin, outcome, pterin, pterin-4a-carbinolamine dehydratase deficiency, sex, tetrahydrobiopterin, treatment, urineSCR_008171(International Database of Tetrahydrobiopterin Deficiencies, RRID:SCR_008171)Last checked downnif-0000-21052
BioBank Central.Resource, data or information resource, biospecimen repository, people resource, service resource, portal, storage service resource, data repository, community building portal, funding resource, material storage repositoryTHIS RESOURCE IS NO LONGER IN SERVICE, documented on March 27, 2013. Web-based portal to connect all the constituencies in the global biobank community. The project seeks to increase the transparency and accessibility of the scientific research process by connecting researchers with an additional source of funding - microinvestments received from the broader online community. In exchange for these public investments, researchers will maintain research logs detailing the play-by-play progress made in their project, as well as publishing all of their data in a public database under a science commons license. These research projects, in turn, will serve to continually update a research-based neuroscience-based human brain & body curriculum. Biobanks are the meeting point of two major information trends in biomedical research: the generation of huge amounts of genomic and other laboratory data, and the electronic capture and integration of patient clinical records. They are comprised of large numbers of human biospecimens supplemented with clinical data. Biobanks when implemented effectively can harness the power of both genomic and clinical data and serve as a critical bridge between basic and applied research, linking laboratory to patient and getting to cures faster. As science and technology leaders work to address the many challenges facing U.S. biobanks logistical, technical, ethical, financial, intellectual property, and IT BioBank Central will serve as an accurate and timely source of knowledge and news about biorepositories and their role in research and drug development. The Web site also provides a working group venue, patient and public education programs, and a forum for international collaboration and harmonization of best practices.biobank, community, biomedical, data, genomic, integration, patient, clinical, human, biospecimen, science, technology, biorepository, drug, development, educationSCR_008645(BioBank Central., RRID:SCR_008645)Open Source Science Project Affymetrix, Bioaccelerate Holdings Inc., FasterCures, Feinstein Kean Healthcare, IBM Healthcare and Life Sciences, Invitrogen CorporationLast checked downnif-0000-32933
American Neurological AssociationResource, topical portal, training resource, people resource, journal article, portal, meeting resource, job resource, data or information resourceThe American Neurological Association is a professional society of academic neurologists and neuroscientists devoted to advancing the goals of academic neurology; to training and educating neurologists and other physicians in the neurologic sciences; and to expanding both our understanding of diseases of the nervous system and our ability to treat them. Our Goals 1. To disseminate knowledge about the nervous system and its diseases by: Presenting new scientific basic and clinical information at an annual meeting Publishing a scientific journal Formulating and promoting high standards of neurologic practice 2. To promote research into the causes and treatment of diseases of the nervous system by: Attracting promising physicians into academic neurology and supporting their development Advocating financial support from government, industry and individuals for research on the nervous system and its disorders 3. To formulate and promote policies and actions which will support the goals of academic neurology by: Providing a unified voice for academic neurology Setting guidelines and assuring excellence in programs that train and educate physicians in neurology Raising the standard of neurologic training of all physicians A few highlights within the portal: Clinical Neuroscience Pathway Startling breakthroughs in molecular biology and basic neuroscience have defined the cause of many diseases of the nervous system and are transforming the practice of neurology, neurosurgery and psychiatry. Basic research is giving new information on how the brain works and how brain injury occurs-and how it can be prevented or improved. Recognizing the exciting opportunities now available to better understand nervous system function and to design new treatments for neurological diseases, we''ve developed an interdepartmental program: The Clinical Neuroscience Pathway to provide an enhanced exposure to the neurosciences while pursuing the Doctor of Medicine degree. Program goal: The Clinical Neuroscience Pathway provides medical students with an enriched experience in the neurosciences throughout their four years in medical school. This program will provide students interested in Neurology, Neurosurgery, Ophthalmology, Pathology, or Psychiatry with access to a number of stimulating clinical and research activities. In addition, students will have the opportunity to participate in activities specifically designed for medical students in the program. Pathway students will be eligible for special summer research and year-out opportunities for clinical and basic neuroscience study. John N. Whitaker Visiting Professorships About the Program The ANA offers up to five 5,000 awards annually to fund visits of several days duration by persons who will interact with medical students and by both formal and informal contacts, stimulate them to consider academic neurology careers. The ideal visitor will be a role model of an accomplished academician who is enthusiastic and will effectively illustrate the applications between basic science and clinical neurology. The ANAs Education Committee must approve the visitor. The inviting institution should have acceptance from the visitor prior to submitting the name. The ANA suggests that an honorarium in the amount of 2,000 be given to the visitor. Special consideration will be given to institutions with small departments, but this is not a requirement. The Whitaker Professorships are intended to honor the life and contributions of John N. Whitaker M.D. (1940 - 2001) whose life and career exemplified high achievement as a person, neurological physician, teacher, investigator, mentor and citizen.fellowships, academic neurologists, basic, clinical, nervous system diseases, neurology, neuroscience, publicationsSCR_012926(American Neurological Association, RRID:SCR_012926)Last checked downnif-0000-10653
EPIGENResource, disease-related portal, topical portal, research forum portal, people resource, patient registry, portal, data or information resourceA group of clinical care and epilepsy research centers who are committed to improving the lives of people with epilepsy through an understanding of the genetics of epilepsy. The consoritum was in an effort to speed discovery to epilepsy genetics by pooling the resources of several research centres. Core Founding Institutes * The Centre for Genomics and Population Genetics. Duke University Institute for Genome Sciences and Policy, North Carolina, USA. (Prof. David Goldstein) * The UCL Institute of Neurology, Queen Square, London, UK. (Prof. Sanjay Sisodiya) * Beaumont Hospital and the Royal College of Surgeons in Ireland. (Dr. Norman Delanty and Dr. Gianpiero Cavalleri) * Hôpital Erasme, Université Libre de Bruxelles, Belgium. (Dr. Chantal Depondt and Prof. Massimo Pandolfo) Collaborating Institutes * The Departments of Medicine and Neurology, The Royal Melbourne Hospital, The University of Melbourne, Victoria, Australia. (Dr. Terence O'Brien and Dr. Cassandra Szoeke) * Murdoch Childrens Research Institute, Department of Paediatrics, The University of Melbourne, Melbourne, Australia. (Dr. Leslie Sheffield) They are currently working on several pharmacogenomic and epilepsy predisposition projects: * The development and implementation of electronic patient records to enhance the quality and efficiency of both patient care and genomics research. * The clinical relevance of genetic variation in vigabatrin induced visual field contriction. * The clinical relevance of genetic variation in weight fluctuation due to anti-convulsant medication. * The role of genetic variation in mesial temporal sclerosis and other "focal" epilepsies. * The potential of magnetic resonance imaging to deliver novel endophenotypes to help resolve the genetic component to epilepsy. The following resources are available to the EPIGEN consortium.. * Over 5000 epilepsy patients recruited from the following hospitals: ** The Institute of Neurology, Queen Square, London, UK. ** Beaumont Hospital, Dublin, Ireland. ** Hopital Erasme, Universite Libre de Bruxelles, Belgium. ** Duke University Hospital, Durham, North Carolina, USA. * Core genotyping facility: The EPIGEN consortium has access to Duke University Institute Genome Sciences and Policy high throughput genotyping facility. Availing of ABI taqman and Illumina Bead Array technology, this facility provides the EPIGEN consortium with genotyping for projects of all sizes. *Statistical support: Research conducted by the EPIGEN consortium can call on statistical support from Duke University IGSP, and the genetics programmes at RCSI and the ION.epilepsy, genetics, gene, mri, genetic variation, clinicalSCR_000093(EPIGEN, RRID:SCR_000093) Free University of Brussels; Brussels; Belgium , Royal College of Surgeons in Ireland; Dublin; Ireland , Beaumont Hospital; Dublin; Ireland , Duke University; North Carolina; USA , University College London; London; United Kingdom EpilepsyLast checked downnlx_143740
Queen Mary University of London Labs and FacilitiesResource, training resource, portal, data or information resourceA collection of laboratory and research facilities in London that cover several domains including but not limited to: biological and chemical sciences, cancer research, condensed matter and material physics, computational research and clinical trials.lab, facility, London, biological, chemical, cancer, computational, clinicalSCR_000234(Queen Mary University of London Labs and Facilities, RRID:SCR_000234)Queen Mary University of London; London; United Kingdom related to: Barts and The London School of Medicine and Dentistry Labs and Facilities, listed by: Science ExchangeLast checked downSciEx_4628
Center for Computational Biology at UCLAResource, organization portal, data access protocol, web service, software resource, portal, atlas, data or information resourceCenter focused on the development of computational biological atlases of different populations, subjects, modalities, and spatio-temporal scales with 3 types of resources: (1) Stand-alone computational software tools (image and volume processing, analysis, visualization, graphical workflow environments). (2) Infrastructure Resources (Databases, computational Grid, services). (3) Web-services (web-accessible resources for processing, validation and exploration of multimodal/multichannel data including clinical data, imaging data, genetics data and phenotypic data). The CCB develops novel mathematical, computational, and engineering approaches to map biological form and function in health and disease. CCB computational tools integrate neuroimaging, genetic, clinical, and other relevant data to enable the detailed exploration of distinct spatial and temporal biological characteristics. Generalizable mathematical approaches are developed and deployed using Grid computing to create practical biological atlases that describe spatiotemporal change in biological systems. The efforts of CCB make possible discovery-oriented science and the accumulation of new biological knowledge. The Center has been divided into cores organized as follows: - Core 1 is focused on mathematical and computational research. Core 2 is involved in the development of tools to be used by Core 3. Core 3 is composed of the driving biological projects; Mapping Genomic Function, Mapping Biological Structure, and Mapping Brain Phenotype. - Cores 4 - 7 provide the infrastructure for joint structure within the Center as well as the development of new approaches and procedures to augment the research and development of Cores 1-3. These cores are: (4)Infrastructure and Resources, (5) Education and Training, (6) Dissemination, and (7) Administration and Management. The main focus of the CCB is on the brain, and specifically on neuroimaging. This area has a long tradition of sophisticated mathematical and computational techniques. Nevertheless, new developments in related areas of mathematics and computational science have emerged in recent years, some from related application areas such as Computer Graphics, Computer Vision, and Image Processing, as well as from Computational Mathematics and the Computational Sciences. We are confident that many of these ideas can be applied beneficially to neuroimaging.functional, genetic, biological system, brain, clinical, computational, computational mathematic, disease, health, image processing, physiological, population, structural, neuroimaging, computational neuroscience, imaging genomics, magnetic resonance, pet, spectSCR_000334(Center for Computational Biology at UCLA, RRID:SCR_000334)Laboratory of Neuro Imaging NCRRrelated to: National Centers for Biomedical Computing, listed by: NeuroImaging Tools and Resources Collaboratory (NITRC)Last checked downnif-0000-10492http://ccb.loni.ucla.edu/http://www.nitrc.org/projects/ccb, http://cms.loni.ucla.edu/CCB/
World Health Organization: The Global Health LibraryResource, bibliography, topical portal, portal, data or information resourceThe Global Health Library assembles health data, readable in many languages. The GHL aims to: * point to reliable information collections and systems, in which different users and user groups (ministries of health, policy makers, health workers, information providers, patients and their families, general public) can focus on the knowledge that best meets their health information needs; * act as a facilitator enabling access to information contents produced by numerous key providers - be they commercial companies, government institutions, civil society, not-for-profit organizations, and regional or international bodies; and * strive for universality, with focus on developing countries, and will act as a resource locator for print materials essential to areas that do not have access to electronic content.clinical, health, human, peopleSCR_000391(World Health Organization: The Global Health Library, RRID:SCR_000391)World Health Organization Last checked downnif-0000-10556http://www.who.int/ghl/en/
NEI Clinical StudiesResource, topical portal, portal, clinical trial, data or information resourceAn archived portal of clinical studies, both ongoing and completed, that have been conducted and supported by the National Eye Institute (NEI) since 1970. The portal covers corneal diseases, glaucoma, epidemiology, lens and cataract, retinal diseases, strabismus, amblyopia and visual processing.eye, clinical, corneal disease, glaucoma, epidemiology, lens, cataract, retinal disease, strabismus, amblyopia, visual processing, clinical trial, research, visionSCR_000546(NEI Clinical Studies, RRID:SCR_000546)National Eye Institute (NEI) Commons Corneal disease, Glaucoma, Cataract, Retinal disease, Strabismus, AmblyopiaNEILast checked downnif-0000-00237http://www.nei.nih.gov/neitrials/index.asp
Jefferson Hospital for Neuroscience Alzheimers Disease and Dementia CenterResource, disease-related portal, topical portal, patient-support portal, portal, data or information resourceIf you or someone you love has been diagnosed with dementia caused by Alzheimer's disease, you'll be in good hands at Jefferson. Our neurologists and psychiatrists are dedicated to: Compassionate care for individuals with Alzheimer's disease; Supporting families; Advancing care through research into the epidemiology and treatment of neurodegenerative diseases. We interact with patients very early in the disease progression, when impairment is typically mild; deliver state-of-the-art care; provide information; build care-giving skills; and help caregivers connect with community support and plan for the future. Although there is no cure for Alzheimer's disease, our goal is to provide accurate diagnoses and state-of-the-art treatment. We are also involved in basic science research that is advancing fundamental knowledge of dementia-related disorders and paving the way for new methods of treatment. At Jefferson Hospital for Neuroscience, patients with Alzheimer's disease can participate in clinical trials with promising investigational treatments for the disease. Most of these studies are multicenter, multiyear trials that have already met a number of rigorous standards for safety and efficacy and have shown favorable effects on memory. For many patients and their families, participation not only offers the hope of slowing the disease but also represents a chance to share personal experience and contribute to new scientific knowledge. Patients who agree to participate must be able to assent to the study, and caregivers who support that participation act as surrogate decision-makers and provide informed consent.alzheimer's disease, late adult human, neurodegenerative disease, dementia, brain bank, clinical trial, clinicalSCR_000579(Jefferson Hospital for Neuroscience Alzheimers Disease and Dementia Center, RRID:SCR_000579)Thomas Jefferson University; Pennsylvania; USA Last checked downnlx_144497http://www.jeffersonhospital.org/departments-and-services/alzheimers-disease-dementia-center.aspx
LORIS - Longitudinal Online Research and Imaging SystemResource, software resource, software application, data management softwareA modular and extensible web-based data management system that integrates all aspects of a multi-center study, from heterogeneous data acquisition to storage, processing and ultimately dissemination, within a streamlined platform. Through a standard web browser, users are able to perform a wide variety of tasks, such as data entry, 3D image visualization and data querying. LORIS also stores data independently from any image processing pipeline, such that data can be processed by external image analysis software tools. LORIS provides a secure web-based and database-driven infrastructure to automate the flow of clinical data for complex multi-site neuroimaging trials and studies providing researchers with the ability to easily store, link, and access significant quantities of both scalar (clinical, psychological, genomic) and multi-dimensional (imaging) data. LORIS can collect behavioral, neurological, and imaging data, including anatomical and functional 3D/4D MRI models, atlases and maps. LORIS also functions as a project monitoring and auditing platform to oversee data acquisition across multiple study sites. Confidentiality during multi-site data sharing is provided by the Subject Profile Management System, which can perform automatic removal of confidential personal information and multiple real-time quality control checks. Additionally, web interactions with the LORIS portal take place over an encrypted channel via SSL, ensuring data security. Additional features such as Double Data Entry and Statistics and Data Query GUI are included.neuroimaging, multi center, data querying, imaging data, platform, computed tomography, neuroinformatics, 3d, 4d, neurological, imaging, mri model, atlas, map, clinical, image processingSCR_000590(LORIS - Longitudinal Online Research and Imaging System, RRID:SCR_000590)McGill University; Montreal; Canada NICHD, NIMH, NINDSlisted by: NeuroImaging Tools and Resources Collaboratory (NITRC)PMID:22319489Last checked downnlx_144608http://www.nitrc.org/projects/loris
NIH - Rapid Access to Interventional DevelopmentResource, production service resource, analysis service resource, material analysis service, biomaterial manufacture, service resource, biomaterial analysis service, material service resource, funding resourceNIH-RAID makes available at no cost to researchers and organizations certain critical resources needed for the development of new therapeutic agents. This program, part of the Translational Research component of Reengineering the Clinical Research Enterprise, uses resources of NCI's Developmental Therapeutics Program and the National Heart Lung and Blood Institutes (NHLBI) Gene Therapy Resource Program. The services provided will depend upon the stage of the project and the strength of the preliminary data. Services available include: production, bulk supply, GMP manufacturing, formulation, development of an assay suitable for pharmacokinetic testing, and animal toxicology. Assistance also will be provided in the regulatory process, through access to independent product development planning expertise. Proposals in support of animal efficacy studies or synthesis and formulation of recombinant proteins or monoclonal antibodies will not be accepted. NIH-RAID is not a grant program. Successful projects will gain access to the governments contract resources, as well as the assistance of the NIH in establishing and implementing a product development plan. Funds to support individual projects will come both from the Roadmap and from individual Institutes, with Institutes assuming the bulk of support in the specific disease areas germane to their mission. This co-sponsorship is critical because of the resource and expertise needs and because NIH-RAID cannot support the full developmental pipeline; an Institute partnership may therefore be important for subsequent translational efforts. To obtain access to NIH-RAID resources, applications must be submitted electronically through Grants.gov using SF424. Applications are initially screened to determine whether the resources requested are appropriate for this program. Then they are reviewed by the NIH Center for Scientific Research. The results of that evaluation along with supplemental information from the lead investigator will guide final Institute and Roadmap resource allocation. The services provided will depend upon the stage of the project and the strength of the preliminary data. When a lead therapeutic agent has been selected and proposed for preclinical development, the following services are available: For small molecules, natural products, peptides, oligonucleotides, and gene vectors: Synthesis, Scale-up production, Development of analytical methods, Development of suitable formulations, Isolation and purification of natural products, Pharmacokinetic/ADME studies including bioanalytical method development, Range-finding initial toxicology, IND-directed toxicology, Manufacture of clinical trial supplies, Product development planning and advice in IND preparation For recombinant proteins and monoclonal antibodies: Pharmacokinetic/ADME studies including bioanalytical method development, Range-finding initial toxicology, IND-directed toxicology, Product development planning and advice in IND preparation When a lead therapeutic agent has not yet been selected and proposed for preclinical development, the following services are available: For small molecules, natural products, peptides, oligonucleotides, and gene vectors: Synthesis, Development of analytical methods, Isolation and purification of natural products, Preliminary Pharmacokinetic/ADME studies, including bioanalytical method development, Preliminary toxicology For recombinant proteins and monoclonal antibodies, Preliminary Pharmacokinetic/ADME studies, including bioanalytical method development, Preliminary toxicology In some cases the NIH-RAID program will support only one or two key steps for preclinical development, while in other cases it may be possible to provide assistance with most of the development tasks needed to file an Investigational New Drug (IND) application to the Food and Drug Administration (FDA). When the NIH-RAID program does not provide all of the remaining services required for IND submission, it is expected that other resources will be in place to complete development steps not supported by NIH-RAID. Funding Resource,.adme, applied, biomaterial method development, clinical, pharmacology, student, toxicologySCR_000713(NIH - Rapid Access to Interventional Development, RRID:SCR_000713)Last checked downnif-0000-00543http://nihroadmap.nih.gov/raid/
California National Primate Research Center Analytical and Resource CoreResource, production service resource, analysis service resource, biomaterial supply resource, material resource, tissue bank, service resource, access service resource, cell repository, reagent supplier, training service resourceThe Analytical and Resource Core provides services and resources to the scientific research community in areas including hematology, clinical chemistry, genetics, immunology, endocrinology, flow cytometry, and pathogen detection. Available resources include biological specimens, viral stocks, DNA, and species-specific reagents. Scientists and staff associated with each of the seven Core Laboratories provide consultation in experimental design, sample collection, and data analysis, and offer assays that utilize species-specific reagents wherever possible. Core Laboratory scientists can also work with users to develop new assays to meet research needs. Training is available for all assays, and Core Laboratories equipment can be made available, typically on a recharge basis. Nonhuman primate resources developed at CNPRC are available to qualified individuals via the Resource Services component of the Core. * Clinical Laboratory * Endocrine Core Laboratory * Flow Cytometry Core Laboratory * Genetics Core Laboratory * Infectious Diseases Immunology Core Laboratory * Pathogen Detection Core Laboratory * Respiratory Disease Immunology Core Laboratory * Affiliated Laboratory: Clinical Proteomics Core Laboratory * Affiliated Laboratory: Microarray Core Facility * Resource Services: The following research resources of CNPRC are available to scientists on a recharge basis. ** Allergen: Characterized protein extracts of house dust mite (Dermatophagoides pteronyssinus and Dermatophagoides farinae) are available for allergen sensitization projects. ** Biological Specimens: Tissues collected at necropsy are available from rhesus monkeys (Macaca mulatta), cynomolgus monkeys (Macaca fascicularis), and titi monkeys (Callicebus cupreus). Contact: Biospecimens (at) primate.ucdavis.edu Blood samples are available through our blood donor program. ** Data: Data for colony animals are available from our computerized database. Data include birth records, weights, reproductive history, relocation history, etc. ** DNA: DNA extracted from peripheral blood mononuclear cells is available on animals of all age-sex classes from known pedigrees. ** Reagents and Samples: Reagents, controls, and known/unknown samples are available from the Pathogen Detection Core Laboratory. Samples include pedigreed sera/plasma, fixed tissues and DNA from macaques and various other species. Validated reagents for many pathogens are available, including SIV, SRV1-5, SFV, STLV, RRV, RhCMV, Herpes B, SV40, and LCV. More information is available at: http://pdl.primate.ucdavis.edu/PDLreagents.html. ** Shipping: Shipping services are available by trained staff who can properly document, package and ship critical experimental materials, including nonhuman primate samples. Assistance is also provided for obtaining CITES permits, required for international shipment of any nonhuman primate samples. ** Transformed B-Cell Lines: Cryopreserved Herpes papio - transformed B cell lines from over 300 rhesus monkeys in the CNPRC colony are available. Transformation of macaque B cells to establish a new cell line is available on request. ** Virus Stock: Rhesus Cytomegalovirus: A unique primary isolate, developed at CNPRC, is available. ** Virus Stock: Simian Immunodeficiency Virus: Aliquots of SIVmac251 and SIVmac239 virus stocks were prepared by propagation in peripheral blood mononuclear cells from rhesus macaques and contain approximately 100,000 50% tissue culture infectious doses per ml. As measured by the commercial SIV branched chain assay, SIVmac251 contains 2 x 109 copies of SIV RNA per ml and SIVmac239 contains 109 copies of SIV RNA per ml. These virus stocks are infectious for rhesus macaques by intravenous, intravaginal and oral routes of inoculation.hematology, clinical chemistry, genetics, immunology, endocrinology, flow cytometry, pathogen detection, consultation, experimental design, sample collection, data analysis, assay development, clinical, endocrine, infectious disease, pathogen, respiratory disease, proteomics, microarray, macaque, siv, srv1-5, sfv, stlv, rrv, rhcmv, herpes b, sv40, lcv, rhesus monkey, cytomegalovirus, simian immunodeficiency virus, herpes papio, long-tailed macaque, south american titi monkeySCR_000696(California National Primate Research Center Analytical and Resource Core, RRID:SCR_000696)California National Primate Research Center Cytomegalovirus, Simian Immunodeficiency Virus, Herpes papio, Respiratory disease, Etc.NCRRlisted by: One Mind Biospecimen Bank ListingLast checked downnlx_151305
ECARUCA ProjectResource, data or information resource, group, databaseA database of cytogenetic and clinical information on rare chromosomal disorders, including microdeletions and microduplications. The database is meant to be easily accessible for all participants, to improve patient care and collaboration between genetic centers, and collect the results of research and clinical features. The acronym ECARUCA stands for "European Cytogeneticists Association Register of Unbalanced Chromosome Aberrations".cytogenetic, clinical, chromosome, gene, microdeletion, microduplication, europe, aberrations, geneticsSCR_000797(ECARUCA Project, RRID:SCR_000797)European Union FP5PMID:16829349Last checked downnif-0000-31901
IFPMA Clinical Trials PortalResource, data or information resource, databaseIFPMA Clinical Trials Portal is brought to you by IFPMA on behalf of its Member Companies and Associations. IFPMA Clinical Trials Portal ensures: a free and easy-to-use interface for patients and health professionals alike to ongoing clinical trials, clinical trial results and complementary information on related issues; non-promotional and reliable information; industry's commitment to the transparency of clinical trials. * Search by Medical Condition and Drug Name * Language Interfaces (En, Es, Fr, De, Jp) * Glossary and Easy Explanation of Medical Expressions * Geographical Searchclinical, clinical trial, pediatric, disease, cancer, hiv, aids, diabetes, heart diseaseSCR_000791(IFPMA Clinical Trials Portal, RRID:SCR_000791)IFPMA - International Federation of Pharmaceutical Manufacturers and Associations IFPMA - International Federation of Pharmaceutical Manufacturers and AssociationsLast checked downnif-0000-31391
CAMDResource, organization portal, consortium, standard specification, narrative resource, portal, data or information resourceA consortium developing new technologies and methods to accelerate the development and review of medical products for neurodegenerative diseases. It is focused on accelerating drug development for patients with chronic neurodegenerative disease, namely, Alzheimer's disease (AD) and Parkinson's disease (PD), by advancing drug development tools for evaluating drug efficacy, conducting clinical trials, and streamlining the process of regulatory review. The consortium focuses on sharing precompetitive patient-level data from the control arms of legacy clinical trials, developing new tools to be submitted to the regulatory agencies, and developing consensus data standards. CAMD has the following areas of focus: (1) qualification of biomarkers, (2) development of common data standards, (3) creation of integrated databases for clinical trials data, and (4) development of quantitative model-based tools for drug development. Regulatory milestones include a qualification opinion with EMA for the use of low baseline hippocampal volume for patient enrichment in pre-dementia trials, and most recently, positive regulatory decisions from the FDA and EMA for the use of a clinical trial simulation tool to aid in trials for mild to moderate stages of AD.data set, clinical trial, mild cognitive impairment, clinical, biomarker, metadata standard, disease progression model, consortium, drug, data sharing, disease modeling, drug development, disease model, imaging, cerebral spinal fluidSCR_001389(CAMD, RRID:SCR_001389)Critical Path Institute; Arizona; USA Publicly fundedlisted by: Consortia-pediaLast checked downnlx_152563
Teen-Longitudinal Assessment of Bariatric Surgery Resource, disease-related portal, topical portal, resource, research forum portal, portal, data or information resourceConsortium made up of five clinical centers and a data coordinating center facilitating coordinated clinical, epidemiological, and behavioral research in the field of adolescent bariatric surgery, through an observational study protocol for uniform data collection pre-operative, at surgery, and through 2 years post-operative at participating centers performing bariatric surgery on teenagers. The use of standardized definitions and data-collection instruments for sequential patients scheduled for surgery at each site will yield meaningful evidence-based recommendations for patient evaluation, selection, and follow-up care. In addition to investigating surgical outcomes, another broader goal of Teen-LABS is to better understand the etiology, pathophysiology, and behavioral aspects of severe obesity in youth and how this condition affects human beings over time. The Teen-LABS consortium members include: Cincinnati Children's Hospital Medical Center, Texas Children's Hospital, Children's Hospital of Alabama, University of Pittsburgh, Nationwide Children's Hospitaladolescent human, bariatrics, pre-operative, at surgery, post-operative, clinical, epidemiology, behavior, surgical outcome, metadata standard, observational study, clinical, experimental protocol, evidence-based recommendation, patient evaluation, follow-up careSCR_001492( Teen-Longitudinal Assessment of Bariatric Surgery , RRID:SCR_001492)Bariatric surgery, ObesityNIDDKlisted by: NIDDK Information Network, submitted by: NIDDK Information NetworkLast checked downnlx_152747
Look AHEAD Resource, resource, clinical trial16-center, randomized clinical trial investigating the long-term health consequences of an intensive lifestyle intervention program designed to achieve and maintain weight loss by decreased caloric intake and increased physical activity in overweight volunteers with type 2 diabetes. The Look AHEAD cohort comprises approximately 5,000 overweight or obese participants with type 2 diabetes, aged 45-76. Participants were randomized to one of two interventions: an intensive lifestyle intervention designed to produce and sustain weight loss over the long term or a diabetes support and education arm. Participants will be followed for a total of 11 to 13.5 years from randomization. The primary hypothesis is that the incidence rate of the first post-randomization occurrence of a composite outcome, which includes * cardiovascular death (including fatal myocardial infarction and stroke), * non-fatal myocardial infarction, * hospitalized angina, and * non-fatal stroke, over a planned follow-up period of up to 13.5 years will be reduced among participants assigned to the Lifestyle Intervention compared to those assigned to the control condition, Diabetes Support and Education. Look AHEAD will also test for reductions in the incidence of three secondary composite outcomes and examine the effect of the intervention on cardiovascular disease risk factors, diabetes control and complications, general health, and quality of life, and psychological outcomes. The cost and cost-effectiveness of the Lifestyle Intervention relative to Diabetes Support and Education will be assessed. The Look AHEAD intensive lifestyle intervention ended September, 2012. Participants continue to be followed to determine the long-term effects of the intervention on health outcomes.weight loss, caloric intake, physical activity, health outcome, long-term effect, longitudinal, intervention, late adult human, middle adult human, cardiovascular disease, risk factor, diabetes control, diabetes complication, health, quality of life, psychological outcome, clinicalSCR_001490( Look AHEAD , RRID:SCR_001490)Wake Forest University; North Carolina; USA Type 2 diabetes, Overweight, ControlNIDDKlisted by: NIDDK Information Network, submitted by: NIDDK Information NetworkLast checked downnlx_152745https://www.lookaheadtrial.org/public/home.cfm
Adult to Adult Living Donor Liver Transplantation Cohort Study Resource, disease-related portal, topical portal, resource, research forum portal, portal, data or information resourceStudy consisting of nine liver transplant centers with expertise in adult living-donor liver transplantation (LDLT) and a central data coordinating center to provide valuable information on the outcomes of adult to adult living donor liver transplantation (AALDLT) to aid decisions made by physicians, patients, and potential donors. The study will establish and maintain the infrastructure required to accrue and follow sufficient numbers of patients being considered for and undergoing AALDLT to provide generalizable data from adequately powered studies. The major aims of A2ALL are as follows: * Quantify the impact of choosing LDLT on the candidate for transplantation * Characterize the difference between LDLT and deceased donor liver transplant (DDLT) in terms of post-transplant outcomes, including patient and graft survival, surgical morbidity, and resource utilization on the recipient of a transplant * Determine the short- and long-term health and quality of life (QOL) impact of donation, including (a) morbidity after liver donation and (b) long-term health-related QOL of donors. * Standardize and assess the role of informed consent in affecting the decision to donate and satisfaction after living liver donation * Other aims include comparison of the severity of recurrence of hepatocellular carcinoma for DDLT versus LDLT, the systematic characterization of liver regeneration and function in donors and recipients, the evaluation of the differences in the immune response to LDLT versus DDLT, and the establishment of a robust data and sample repository on liver transplantation that may be used to study clinical and biological questions as new technologies and resources become available. Patients enrolled in the study will be followed and managed in a standardized fashion.transplant, liver, adult human, risk factor, surgery, outcome, quality of life, clinicalSCR_001494( Adult to Adult Living Donor Liver Transplantation Cohort Study , RRID:SCR_001494)University of Michigan; Michigan; USA Liver transplant, Liver diseaseNIDDKlisted by: NIDDK Information Network, submitted by: NIDDK Information NetworkReferences (3)Last checked downnlx_152749
X
  1. RRID Portal Resources

    Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.

  2. Navigation

    You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.

  3. Logging in and Registering

    If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.

  4. Searching

    Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:

    1. Use quotes around phrases you want to match exactly
    2. You can manually AND and OR terms to change how we search between words
    3. You can add "-" to terms to make sure no results return with that term in them (ex. Cerebellum -CA1)
    4. You can add "+" to terms to require they be in the data
    5. Using autocomplete specifies which branch of our semantics you with to search and can help refine your search
  5. Collections

    If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.

  6. Facets

    Here are the facets that you can filter the data by.

  7. Further Questions

    If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.